Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review

References

• Vijaya B, Roberto V, Julie V. In: Chapter 81 - Mantle Cell Lymphoma. Hoffman R, Benz EJ, Silberstein LE, et al., editors. Syed Ali Abutalib, Hematology. 7th ed. Elsevier; 2018:1298–1308.e2. ISBN 9780323357623. Available from: https://clicktime.symantec.com/3W32RBpPF6to7qfkhD6ogaC7Vc?u=https%3A%2F%2Fdoi.org%2F10.1016%2FB978-0-323-35762-3.00081-0. Accessed November 14, 2023.
   Google Scholar
• Wang Y, Ma S. Racial differences in mantle cell lymphoma in the United States. BMC Cancer. 2014;14:764. doi:10.1186/1471-2407-14-764
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113(4):791–798. doi:10.1002/cncr.23608
   PubMed Web of Science ®Google Scholar
• Lynch DT, Acharya U. Mantle cell lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536985/. Accessed November 14, 2023.
   Google Scholar
• Ye H, Desai A, Zeng D, et al. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res. 2017;36(1):185. doi:10.1186/s13046-017-0652-8
   PubMedGoogle Scholar
• Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6(1):24. doi:10.1186/1476-4598-6-24
   PubMed Web of Science ®Google Scholar
• Ott G, Kalla J, Ott MM, et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood. 1997;89(4):1421–1429. doi:10.1182/blood.V89.4.1421
   PubMed Web of Science ®Google Scholar
• Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87(10):4302–4310. doi:10.1182/blood.V87.10.4302.bloodjournal87104302
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Lin KI, Kuo TC, et al. Blimp −1 orchestrates plasma cell differentiation by extinguishing the mature B cel gl gene expression program. Immunity. 2002;17(1):51–62. doi:10.1016/S1074-7613(02)00335-7
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma [published correction appears in Cancer. 2003 Jun 15;97(12):3131]. Cancer. 2003;97(3):586–591. doi:10.1002/cncr.11096
   PubMed Web of Science ®Google Scholar
• Ferrer A, Salaverria I, Bosch F, et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer. 2007;109(12):2473–2480. doi:10.1002/cncr.22715
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780–2795. doi:10.1200/JCO.1998.16.8.2780
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma [published correction appears in Blood. 2008 Jun 15;111(12):5761]. Blood. 2008;111(2):558–565. doi:10.1182/blood-2007-06-095331
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115(8):1530–1533. doi:10.1182/blood-2009-08-236570
   PubMed Web of Science ®Google Scholar
• Bond DA, Martin P, Maddocks KJ. Relapsed mantle cell lymphoma: current management, recent progress, and future directions. J Clin Med. 2021;10(6):1207. doi:10.3390/jcm10061207
   PubMed Web of Science ®Google Scholar
• Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9(6):50. doi:10.1038/s41408-019-0209-5
   PubMed Web of Science ®Google Scholar
• Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study [published correction appears in Leukemia. 2021 Jan 22;:]. Leukemia. 2021;35(3):787–795. doi:10.1038/s41375-020-01013-3
   PubMed Web of Science ®Google Scholar
• Corneth OBJ, Klein Wolterink RGJ, Hendriks RW. BTK Signaling in B Cell Differentiation and Autoimmunity. Curr Top Microbiol Immunol. 2016;393:67–105. doi:10.1007/82_2015_478
   PubMed Web of Science ®Google Scholar
• Kim HO. Development of BTK inhibitors for the treatment of B-cell malignancies. Arch Pharm Res. 2019;42(2):171–181. doi:10.1007/s12272-019-01124-1
   PubMed Web of Science ®Google Scholar
• Chang BY, Francesco M, De Rooij MF, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122(14):2412–2424. doi:10.1182/blood-2013-02-482125
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Food and Drug Administration grants have accelerated the approval of zanubrutinib for mantle cell lymphoma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma. Accessed November 20, 2020.
   Google Scholar
• BRUKINSA (Zanubrutinib) [prescribing information]. San Mateo, CA: BeiGene USA, Inc.; 2019.
   Google Scholar
• National Comprehensive Cancer Network (NCCN). B-cell lymphomas. Version 6; 2023. Available from: www.nccn.org. Accessed September 24, 2023.
   Google Scholar
• BRUKINSA (zanubrutinib) [package insert]. San Mateo, CA: BeiGene, Ltd; 2019.
   Google Scholar
• Zou Y, Zhu H, Li X, et al. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Hematol Oncol. 2019;37(4):392–400. doi:10.1002/hon.2667
   PubMed Web of Science ®Google Scholar
• Tam C, Grigg AP, Opat S, et al. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/ refractory B-cell malignancies: initial report of a phase 1 first-in-human trial [abstract]. Blood. 2015;126(23):Abstract 832. doi:10.1182/blood.V126.23.832.832
   Google Scholar
• Tam C, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851–859. doi:10.1182/blood.2019001160
   PubMed Web of Science ®Google Scholar
• Wu J, Liu C, Tsui ST, Liu D. Second‐generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9(1):80. doi:10.1186/s13045-016-0313-y
   PubMed Web of Science ®Google Scholar
• Handunnetti SM, Tang CPS, Nguyen T, et al. BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib. Blood. 2019;134(Supplement_1):170. doi:10.1182/blood-2019-125488
   Google Scholar
• Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175–1179. doi:10.1093/annonc/mdv111
   PubMed Web of Science ®Google Scholar
• Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling identifies NF‐κB‐targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20(1):87–92. doi:10.1038/nm.3435
   PubMed Web of Science ®Google Scholar
• Balasubramanian S, Schaffer M, Deraedt W, et al. Mutational analysis of patients with primary resistance to single‐agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL). Blood. 2014;124(21):78. doi:10.1182/blood.V124.21.78.78
   Web of Science ®Google Scholar
• Lenz G, Balasubramanian S, Goldberg J, et al. Sequence variants in patients with primary and acquired resistance to ibrutinib in the Phase 3 MCL 3001 (RAY) trial. J Clin Oncol. 2016;34(suppl):abstr 7570. doi:10.1200/JCO.2016.34.15_suppl.7570
   Google Scholar
• Estupinan HY, Wang Q, Berglof A, et al. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia. 2021;35(5):1317–1329. doi:10.1038/s41375-021-01123-6
   PubMed Web of Science ®Google Scholar
• Sayed YY. Zanubrutinib: first Approval. Drugs. 2020;80(1):91–97. doi:10.1007/s40265-019-01252-4
   PubMed Web of Science ®Google Scholar
• Weaver AN, Jimeno A. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma. Drugs Today. 2020;56(8):531–539. doi:10.1358/dot.2020.56.8.3158047
   PubMed Web of Science ®Google Scholar
• Ou YC, Tang Z, Novotny W, et al. Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. Leuk Lymphoma. 2021;62(11):2612–2624. doi:10.1080/10428194.2021.1929961
   PubMed Web of Science ®Google Scholar
• Flinsenberg TWH, Tromedjo CC, Hu N, et al. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica. 2020;105(2):e76–e79. doi:10.3324/haematol.2019.220590
   PubMed Web of Science ®Google Scholar
• Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577–2585. doi:10.1182/bloodadvances.2020004074
   PubMed Web of Science ®Google Scholar
• Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148–3158. doi:10.1182/blood.2021014162
   PubMed Web of Science ®Google Scholar
• Dreyling M, Tam CS, Wang M, et al. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021;17(3):255–262. doi:10.2217/fon-2020-0794
   PubMedGoogle Scholar
• Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031–1043. doi:10.1016/S1470-2045(22)00293-5
   PubMed Web of Science ®Google Scholar
• Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021 Virtual Congress. Abstract LB1900. June 11; 2021.
   Google Scholar
• Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6(4):1296–1308. doi:10.1182/bloodadvances.2021005621
   PubMed Web of Science ®Google Scholar
• Lexicomp Online [online database]. Hudson, OH: Lexi-Comp; 2022.
   Google Scholar
• Tam CS, Wallis N, Zhang M, et al. Rate of atrial fibrillation in patients with B-cell malignancies who undergo treatment with zanubrutinib. Am J Hematol. 2022;97:525–526. doi:10.1002/ajh.26736
   Web of Science ®Google Scholar
• Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol. 2023;10(1):e35–e45. doi:10.1016/S2352-3026(22)00320-9
   PubMed Web of Science ®Google Scholar
• Alrawashdh N, McBride A, Slack M, Persky D, Andritsos L, Abraham I. Cost-effectiveness and value of information analyses of Bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States. J Manag Care Spec Pharm. 2022;28(4):390–400. doi:10.18553/JMCP.2022.28.4.390/ASSET/IMAGES/SMALL/FIG2.GIF
   PubMed Web of Science ®Google Scholar